Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05162391 · ClinicalTrials.gov registry record · NA
Inflammation in Methamphetamine and STIs (IMSTI)
A NA study of Methamphetamine-dependence and Rectal Gonorrhea, sponsored by University of California, Los Angeles.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05162391: Active NA study of Methamphetamine-dependence and Rectal Gonorrhea, sponsored by University of California, Los Angeles.
NCT05162391 is a NA study of Methamphetamine-dependence and Rectal Gonorrhea that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 30 participants, below the 105-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05162391, a NA study of Methamphetamine-dependence and Rectal Gonorrhea, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial aims to investigate the effects of a decline in methamphetamine use on rectal inflammatory cytokine levels, substance use contexts, and HIV/STI risk behavior. This clinical trial also seeks to evaluate joint effects of methamphetamine use and rectal gonorrhea/chlamydia infection on rectal inflammatory cytokine levels. The proposed trial will consist of 40 MSM, half with rectal gonorrhea/chlamydia infection at enrollment (n=20), with methamphetamine use disorder that will receive contingency management for methamphetamine reduction. Following baseline measurement, participants will be observed over the course of 8 weeks, where participants will complete behavioral surveys, provide urine for drug testing, and rectal samples for measurement of rectal inflammatory cytokine levels.
Primary Outcome
Percentage of visits in which there are no detectable methamphetamine metabolites in participant urine samples
Conditions Studied
Interventions
- BEHAVIORAL Contingency Management
Study Locations (1)
California
- UCLA Vine Street Clinic - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-05-31 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What the registry record for NCT05162391 still lists
NCT05162391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 105-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (71% lower).
The record links to 3 conditions, with Methamphetamine-dependence appearing as the primary indexed condition, and to 1 intervention - of which Contingency Management is the first listed.
NCT05162391 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05162391 about?
NCT05162391 is a clinical study titled "Inflammation in Methamphetamine and STIs (IMSTI)". This clinical trial aims to investigate the effects of a decline in methamphetamine use on rectal inflammatory cytokine levels, substance use contexts, and HIV/STI risk behavior. This clinical trial also seeks to evaluate joint effects of methamphetamine use and rectal gonorrhea/chlamydia infection ...
What is the current status of trial NCT05162391?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-05-31. Estimated completion is 2027-06-30.
What conditions does trial NCT05162391 study?
This clinical trial studies the following conditions: Methamphetamine-dependence, Rectal Gonorrhea, Rectal Chlamydia.
What interventions are being tested in trial NCT05162391?
The interventions under investigation include: Contingency Management (BEHAVIORAL).
Who is sponsoring clinical trial NCT05162391?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05162391 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine-dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05162391's enrollment target sits among peer trials
30 9th of 18 higher than 8 of 18 other Methamphetamine-dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Methamphetamine-dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
RECRUITING · NA
-
rTMS for Craving in Methamphetamine Use Disorder
RECRUITING · NA
-
MHealth Incentivized Adherence Plus Patient Navigation
ACTIVE NOT RECRUITING · NA
-
The Human Stress Response in a Simulated ED Setting
ACTIVE NOT RECRUITING · NA
-
Pilot TMS for Methamphetamine Use Disorder
COMPLETED · NA
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI